GENFIT
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
GENFIT is a late-stage biopharmaceutical company dedicated to discovering and developing therapeutic and diagnostic solutions for patients with rare and life-threatening liver diseases. With a scientific heritage spanning over two decades, the company has established a diversified pipeline focused on conditions with high unmet medical needs. GENFIT is a leader in developing treatments for Acute-on-Chronic Liver Failure (ACLF) and its complications, such as Hepatic Encephalopathy. The company's R&D portfolio also includes programs for Cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD). A key achievement is the successful development of elafibranor for Primary Biliary Cholangitis (PBC), which is now being commercialized by a partner. In addition to therapeutics, GENFIT has a diagnostic franchise focusing on metabolic liver diseases (MASH/NASH) and ammonia.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-22 22:00 |
Interim Report
Attestation de la personne responsable associée au rapport d'activité et financ…
|
French | 118.9 KB | ||
| 2025-06-17 20:30 |
Post-Annual General Meeting Information
GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025
|
French | 140.4 KB | ||
| 2025-06-17 20:30 |
Post-Annual General Meeting Information
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
|
English | 140.0 KB | ||
| 2025-05-22 22:10 |
Quarterly Report
GENFIT Reports First Quarter 2025 Financial Information
|
English | 163.4 KB | ||
| 2025-05-22 22:10 |
Earnings Release
GENFIT : Information financière du premier trimestre 2025
|
French | 146.7 KB | ||
| 2025-05-20 22:10 |
Regulatory News Service
GENFIT to receive a €26.5 million milestone payment following the approval of p…
|
English | 143.6 KB | ||
| 2025-05-20 22:10 |
Regulatory News Service
GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l…
|
French | 137.3 KB | ||
| 2025-05-14 22:10 |
Environmental & Social Information
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year…
|
English | 793.3 KB | ||
| 2025-05-07 22:10 |
Pre-Annual General Meeting Information
GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposi…
|
French | 129.1 KB | ||
| 2025-05-07 22:10 |
Pre-Annual General Meeting Information
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Prepa…
|
English | 135.6 KB | ||
| 2025-05-05 07:30 |
Environmental & Social Information
GENFIT présentera ses dernières avancées dans l'ACLF à l’EASL Congress 2025
|
French | 228.8 KB | ||
| 2025-05-05 07:30 |
Regulatory News Service
GENFIT to Present Latest ACLF Research at EASL Congress 2025
|
English | 220.7 KB | ||
| 2025-04-29 21:10 |
Registration Form
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2024 et du R…
|
French | 516.5 KB | ||
| 2025-04-29 21:10 |
Report Publication Announcement
GENFIT Announces Publication of the 2024 Universal Registration Document and th…
|
English | 648.6 KB | ||
| 2025-04-29 12:14 |
Annual Report (ESEF)
Document d'Enregistrement Universel 2024
|
French | 10.4 MB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
